Abstract:Epidemiological, preclinical and cellular studies in the last 5 years have shown that metformin exerts anti-tumoral properties, but its mode of action in cancer remains unclear. Here, we investigated the effects of metformin on a mouse hepatocellular carcinoma (HCC) model and tumor-associated T cell immune responses. Oral metformin administration led to a significant reduction of tumor growth, which was accompanied by decreased interleukin-22 (IL-22). Meanwhile, IL-22-induced STAT3 phosphorylation and upregulation of downstream genes Bcl-2 and cyclin D1 were inhibited by metformin. At the cellular level, metformin attenuated Th1- and Th17-derived IL-22 production. Furthermore, metformin inhibited de novo generation of Th1 and Th17 cells from naive CD4(+) cells. These observations were further supported by the fact that metformin treatment inhibited CD3/CD28-induced IFN- and IL-17A expression along with the transcription factors that drive their expression (T-bet [Th1] and ROR-t [Th17], respectively). The effects of metformin on T cell differentiation were mediated by downregulated STAT3 and STAT4 phosphorylation via the AMP-activated kinase-mammalian target of rapamycin complex 1 pathway. Notably, metformin led to a reduction in glucose transporter Glut1 expression, resulting in less glucose uptake, which is critical to regulate CD4(+) T cell fate. Taken together, these findings provide evidence for the growth-inhibitory and immune-modulatory effects of metformin in HCC and thus, broaden our understanding about the action of metformin in liver cancer treatment.What's new? Over the last decade, metformin, an anti-diabetic drug, has gained significant attention as an anti-cancer drug because of its association with a dramatically decreased risk of some cancers. The underlying mechanisms of action, however, remain largely unknown. Here, using a mouse hepatocellular carcinoma (HCC) model, the authors found an important and previously unidentified effect of metformin with the inhibition of HCC growth through an indirect path mediated by IL-22. The findings also provide evidence for immune-modulatory effects of metformin in HCC. Taken together, these data broaden our current understanding of the mechanisms of action of metformin in liver cancer treatment.

Metformin Promotes Anticancer Activity of NK Cells in a P38 MAPK Dependent Manner

Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition

Metformin plays an antitumor role by downregulating inhibitory cells and immune checkpoint molecules while activating protective immune responses in breast cancer

Potential Effect of EGCG on the Anti-Tumor Efficacy of Metformin in Melanoma Cells

Abstract 6636: Metformin suppresses tumor immune evasion through downregulation of PD-L1 expression in cancer cells and PD-1 expression in NK cells and T cells

Metformin promotes anti-tumor immunity in STK11 mutant NSCLC through AXIN1-dependent upregulation of multiple nucleotide metabolites

Metformin-treated cancer cells modulate macrophage polarization through AMPK-NF-κB signaling

Harnessing Metformin's Immunomodulatory Effects on Immune Cells to Combat Breast Cancer

Metformin Decreases Il-22 Secretion To Suppress Tumor Growth In An Orthotopic Mouse Model Of Hepatocellular Carcinoma

Metabolomics profiling of metformin-mediated metabolic reprogramming bypassing AMPKα

Metformin Displays Anti-Myeloma Activity and Synergistic Effect with Dexamethasone in in Vitro and in Vivo Xenograft Models.

Metformin suppresses cancer cell growth in endometrial carcinoma by inhibiting PD-L1

Dual Blockade of Lactate/GPR81 and PD-1/PD-L1 Pathways Enhances the Anti-Tumor Effects of Metformin

PlGF Signaling and Macrophage Repolarization Contribute to the Anti-Neoplastic Effect of Metformin

Metformin impacts the differentiation of mouse bone marrow cells into macrophages affecting tumour immunity

Metformin Enhances Radiation Response of ECa109 Cells Through Activation of ATM and AMPK

Metformin enhances T lymphocyte anti-tumor immunity by increasing the infiltration via vessel normalization

Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways

Metformin Attenuates Hepatoma Cell Proliferation by Decreasing Glycolytic Flux Through the HIF-1α/PFKFB3/PFK1 Pathway.

Metformin is Associated with Reduced Cell Proliferation in Human Endometrial Cancer by Inbibiting PI3K/AKT/mTOR Signaling.

Therapeutic Metformin/ampk Activation Blocked Lymphoma Cell Growth Via Inhibition of Mtor Pathway and Induction of Autophagy